1
|
Effects of Transitioning to Medicare Part D on Access to Drugs for Medical Conditions among Dual Enrollees with Cancer. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2017; 20:1345-1354. [PMID: 29241894 PMCID: PMC5734096 DOI: 10.1016/j.jval.2017.05.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Revised: 05/19/2017] [Accepted: 05/25/2017] [Indexed: 06/07/2023]
Abstract
OBJECTIVES To evaluate the impact of transitioning from Medicaid to Medicare Part D drug coverage on the use of noncancer treatments among dual enrollees with cancer. METHODS We leveraged a representative 5% national sample of all fee-for-service dual enrollees in the United States (2004-2007) to evaluate the impact of the removal of caps on the number of reimbursable prescriptions per month (drug caps) under Part D on 1) prevalence and 2) average days' supply dispensed for antidepressants, antihypertensives, and lipid-lowering agents overall and by race (white and black). RESULTS The removal of drug caps was associated with increased use of lipid-lowering medications (days' supply 3.63; 95% confidence interval [CI] 1.57-5.70). Among blacks in capped states, we observed increased use of lipid-lowering therapy (any use 0.08 percentage points; 95% CI 0.05-0.10; and days' supply 4.01; 95% CI 2.92-5.09) and antidepressants (days' supply 2.20; 95% CI 0.61-3.78) and increasing trends in antihypertensive use (any use 0.01 percentage points; 95% CI 0.004-0.01; and days' supply 1.83; 95% CI 1.25-2.41). The white-black gap in the use of lipid-lowering medications was immediately reduced (-0.09 percentage points; 95% CI -0.15 to -0.04). We also observed a reversal in trends toward widening white-black differences in antihypertensive use (level -0.08 percentage points; 95% CI -0.12 to -0.05; and trend -0.01 percentage points; 95% CI -0.02 to -0.01) and antidepressant use (-0.004 percentage points; 95% CI -0.01 to -0.0004). CONCLUSIONS Our findings suggest that the removal of drug caps under Part D had a modest impact on the treatment of hypercholesterolemia overall and may have reduced white-black gaps in the use of lipid-lowering and antidepressant therapies.
Collapse
|
2
|
Projected Savings and Workforce Transformation from Converting Independence at Home to a Medicare Benefit. J Am Geriatr Soc 2016; 64:1531-6. [DOI: 10.1111/jgs.14176] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
3
|
Association of a Claims-Based Marker of Functional Impairment With Treatment Patterns and Cost in Metastatic Squamous Cell Carcinoma of the Head and Neck (mSCCHN). Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2015.12.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
4
|
|
5
|
Sidney Schulman, MD (1923-2014). Neurology 2014. [DOI: 10.1212/wnl.0000000000000533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
6
|
Hilary Koprowski, MD (1916-2013). Neurology 2013; 81:612-3. [DOI: 10.1212/wnl.0b013e3182a08fba] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
7
|
|
8
|
|
9
|
Abstract
Varicella zoster virus (VZV) is a neurotropic herpesvirus that infects nearly all humans. Primary infection usually causes chickenpox (varicella), after which virus becomes latent in cranial nerve ganglia, dorsal root ganglia and autonomic ganglia along the entire neuraxis. Although VZV cannot be isolated from human ganglia, nucleic acid hybridization and, later, polymerase chain reaction proved that VZV is latent in ganglia. Declining VZV-specific host immunity decades after primary infection allows virus to reactivate spontaneously, resulting in shingles (zoster) characterized by pain and rash restricted to one to three dermatomes. Multiple other serious neurological and ocular disorders also result from VZV reactivation. This review summarizes the current state of knowledge of the clinical and pathological complications of neurological and ocular disease produced by VZV reactivation, molecular aspects of VZV latency, VZV virology and VZV-specific immunity, the role of apoptosis in VZV-induced cell death and the development of an animal model provided by simian varicella virus infection of monkeys.
Collapse
|
10
|
Abstract
OBJECTIVE Varicella zoster virus (VZV) is an under-recognized yet treatable cause of stroke. No animal model exists for stroke caused by VZV infection of cerebral arteries. Thus, we analyzed cerebral and temporal arteries from 3 patients with VZV vasculopathy to identify features that will help in diagnosis and lead to a better understanding of VZV-induced vascular remodeling. METHODS Normal and VZV-infected cerebral and temporal arteries were examined histologically and by immunohistochemistry using antibodies directed against VZV, endothelium, and smooth muscle actin and myosin. RESULTS All VZV-infected arteries contained 1) a disrupted internal elastic lamina; 2) a hyperplastic intima composed of cells expressing α-smooth muscle actin (α-SMA) and smooth muscle myosin heavy chain (SM-myosin) but not endothelial cells expressing CD31; and 3) decreased medial smooth muscle cells. The location of VZV antigen, degree of neointimal thickening, and disruption of the media were related to the duration of disease. CONCLUSIONS The presence of VZV primarily in the adventitia early in infection and in the media and intima later supports the notion that after reactivation from ganglia, VZV spreads transaxonally to the arterial adventitia followed by transmural spread of virus. Disruption of the internal elastic lamina, progressive intimal thickening with cells expressing α-SMA and SM-MHC, and decreased smooth muscle cells in the media are characteristic features of VZV vasculopathy. Stroke in VZV vasculopathy may result from changes in arterial caliber and contractility produced in part by abnormal accumulation of smooth muscle cells and myofibroblasts in thickened neointima and disruption of the media.
Collapse
|
11
|
Abstract
Declining cell-mediated immunity to varicella zoster virus (VZV) in elderly individuals results in virus reactivation manifest by zoster (shingles) and postherpetic neuralgia (PHN). To prevent virus reactivation, a new VZV vaccine (Zostavax; Merck) that boosts cell-mediated immunity to VZV was developed. The 3-year Shingles Prevention Study showed that Zostavax significantly reduced burden of disease because of zoster and PHN. Despite its cost-effectiveness for adults aged 65-75 years, as determined in the United States, Canada and UK, <2% of immunocompetent adults over age 60 years in the United States were immunized in 2007. This was because of a combination of lack of patient awareness of the vaccine, physicians' uncertainty about the duration of protection and different cost-sharing plans for immunization. Nevertheless, zoster vaccine is safe, effective and highly recommended for immunization of immunocompetent individuals over age 60 years with no history of recent zoster.
Collapse
|
12
|
Zoster sine herpete: virologic verification by detection of anti-VZV IgG antibody in CSF. Neurology 2011; 76:484-5. [PMID: 21282595 DOI: 10.1212/wnl.0b013e31820a0d28] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
13
|
Virus vasculopathy and stroke: an under-recognized cause and treatment target. Infect Disord Drug Targets 2010; 10:105-111. [PMID: 20166970 PMCID: PMC2909030 DOI: 10.2174/187152610790963537] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2009] [Accepted: 10/07/2009] [Indexed: 05/28/2023]
Abstract
While arteriosclerotic disease and hypertension, with or without diabetes, are the most common causes of stroke, viruses may also produce transient ischemic attacks and stroke. The three most-well studied viruses in this respect are varicella zoster virus (VZV), cytomegalovirus (CMV) and human immunodeficiency virus (HIV), all of which are potentially treatable with antiviral agents. Productive VZV infection in cerebral arteries after reactivation (zoster) or primary infection (varicella) has been documented as a cause of ischemic and hemorrhagic stroke, aneurysms with subarachnoid and intracerebral hemorrhage, arterial ectasia and as a co-factor in cerebral arterial dissection. CMV has been suggested to play a role in the pathogenesis of arteriosclerotic plaques in cerebral arteries. HIV patients have a small but definite increased incidence of stroke which may be due to either HIV infection or opportunistic VZV infection in these immunocompromised individuals. Importantly, many described cases of vasculopathy in HIV-infected patients were not studied for the presence of anti-VZV IgG antibody in CSF, a sensitive indicator of VZV vasculopathy. Unlike the well-documented role of VZV in vasculopathy, evidence for a causal link between HIV or CMV and stroke remains indirect and awaits further studies demonstrating productive HIV and CMV infection of cerebral arteries in stroke patients. Nonetheless, all three viruses have been implicated in stroke and should be considered in clinical diagnoses.
Collapse
|
14
|
Abstract
OBJECTIVE Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus that becomes latent in B-lymphocytes and has been implicated in the pathogenesis of multiple sclerosis (MS). We searched for latent and active EBV infection in MS brain and CSF. METHODS Nested and non-nested real-time PCR were used to detect cell-specific and EBV-specific transcripts in 15 fresh-frozen and 5 formalin-fixed paraffin-embedded MS plaques and in single MS CSF B-lymphocytes and plasma cells. Intrathecal anti-EBV antibody synthesis was measured by ELISA. Immunocytochemistry was used to detect binding of MS CSF and recombinant antibodies (rAbs) generated from clonally expanded plasma cells in MS CSF to EBV-infected cells. RESULTS No EBV RNA was found in MS CSF B-lymphocytes or plasma cells. In active MS plaques, EBV-encoded RNA (EBER)-1 was the only and rarely detected transcript. The frequency of detected intrathecal anti-EBV antibody synthesis in patients with MS did not differ from that in non-MS inflammatory CNS disease control patients. Anti-EBV antibodies were detected in the CSF of patients with MS, but MS rAbs did not react with EBV. CONCLUSIONS Application of real-time PCR to multiple sclerosis brain and single B-lymphocytes in CSF did not reveal any evidence of active Epstein-Barr virus infection.
Collapse
|
15
|
|
16
|
Abstract
This study assesses cost of illness of metastatic breast cancer (MBC) patients over a specific period of time as observed in Medicare program expenditure data. Incident cases of MBC from 1997 to 1999 were included. Direct care cost data were obtained from Medicare claims from a 5% national sample of program beneficiaries. Costs to the health care system were determined from the date of first diagnosis of MBC to the end of follow-up. A matched case-control study provided comparison of Medicare payments in cancer and non-cancer patients. A total of 397 MBC patients were identified and followed for an average of 16.2 months. The mean total cost was US$ 35,164 per MBC patient and US$ 4176 per person for the control group. Over the follow-up period, the MBC patients averaged 1.7 inpatient admissions per patient and 14.4 inpatient days per admission. The control group averaged 0.3 inpatient admissions per patient and 1.6 inpatient days per admission. Home health aide for MBC averaged one visit every 2 weeks. The direct costs for the older MBC patients were less than the direct costs of the younger MBC group. Multivariate regression analysis showed that as the age increased, the Medicare costs decreased within the MBC cohorts. Less combination treatments were provided for older MBC patients. Cost of illness was inversely proportional to age.
Collapse
|
17
|
Dual protease inhibitors gain ground. BETA : BULLETIN OF EXPERIMENTAL TREATMENTS FOR AIDS : A PUBLICATION OF THE SAN FRANCISCO AIDS FOUNDATION 2002; 14:17-24. [PMID: 11693084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
|
18
|
|
19
|
A long march, in unknown territory, to an uncertain end. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 2001; 12:1-2. [PMID: 11364983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
20
|
The medical merry-go-round: drugs for 1998 are new but not novel. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 2001; 12:18-25. [PMID: 11364984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
21
|
Tenofovir: Gilead applies for approval; expanded access liberalized. AIDS TREATMENT NEWS 2001:2-3, 1. [PMID: 11569959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
Patients who cannot construct a viable antiretroviral regimen with approved drugs will now have easier access to tenofovir, a drug that is currently experimental but may be approved in about six months. Tenofovir is significant because it appears to maintain its antiretroviral activity, with resistant HIV developing relatively slowly.
Collapse
|
22
|
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. Clin Ther 2001; 23:727-43. [PMID: 11394731 DOI: 10.1016/s0149-2918(01)80022-9] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
BACKGROUND Treatment of benign prostatic hyperplasia (BPH) with nonselective alpha1 antagonists such as terazosin, doxazosin, and prazosin results in blood pressure reduction due to vasodilation. OBJECTIVE Using claims data from a large Medigap plan, we examined the effect of initiating nonselective alpha1-antagonist therapy on the incidence of hypotension-related adverse events likely to be associated with vascular alpha-adrenoreceptor antagonism in patients with BPH. METHODS Medical and prescription claims data were obtained from the MEDSTAT Group for 53,824 men with a diagnosis code for BPH during the study period (January 1995-December 1997). We examined the rate of possible hypotension-related adverse events (diagnosis codes for hypotension, syncope, dizziness, fractures, and other injuries) per 10,000 person-days for men who began therapy with alpha1 antagonists and for a random sample of nonusers, stratified by prior use of other antihypertensive agents. RESULTS After adjusting for baseline differences in event rates, those who initiated alpha1-antagonist therapy (n = 1564) had a significantly greater increase in hypotension-related adverse-event rates in the 4 months after initiation (vs the 4 months before initiation) than randomly selected nonusers (n = 8641) (increase of 1.82 vs decrease of 0.02 events per 10,000 person-days among those not taking antihypertensive agents; increase of 0.94 vs 0.69 events per 10,000 person-days among those taking other antihypertensive agents; P < 0.01). This increase began earlier and lasted longer among patients taking other antihypertensive agents. Those who discontinued their alpha1 antagonist had a higher rate of hypotensive events at baseline than those who did not (5.09 vs 3.19 events per 10,000 person-days among those using other antihypertensive agents; 3.62 vs 2.27 events per 10,000 person-days among those not using other antihypertensive agents; P < 0.05). CONCLUSIONS Initiation of nonselective alpha1-antagonist therapy for the treatment of BPH increases the risk of a cluster of clinical events consistent with vascular alpha-adrenoreceptor antagonism. This effect is seen during a 4-month period around the initiation date. Prior initiation of other antihypertensive medication increases this effect. Urologists should consult with a patient's primary care physician about use of other antihypertensive agents before initiating nonselective alpha1-antagonist therapy for BPH.
Collapse
|
23
|
"KnowWare: virtual reality maps for blind people". Stud Health Technol Inform 1999; 62:191-7. [PMID: 10538355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
Much has been done to give blind people access to text-based information through computers. Unfortunately, the recent development of Windows operating systems and GUIs jeopardize these gains. Spatial information which is becoming more important to the sighted has never been widely available to blind people. Through a combination of gesture input with audio output, the KnowWare system offers blind users a new way to access spatial information. An invisible virtual map is defined on the desktop. When the user touches a feature on the map with the tip of his index finger, the computer tells him what he has touched by means of computer-generated speech or synthesized sound codes. Touching is detected by means of an overhead video camera that looks down at the user's hands as they rest upon the desktop. Specialized processors analyze the image of the user's hands and locate the fingertips. Because KnowWare is an electronic medium, it is possible to instantly zoom in on a particular state or country to examine it in more detail. Similarly, panning and overlays are possible. Twenty blind subjects have tested KnowWare and have been able to use it as well as they do traditional raised-line maps.
Collapse
|
24
|
More trouble for adefovir. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1999; 13:3. [PMID: 11366975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
25
|
Taking a break when all else fails. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1999; 13:1-3. [PMID: 11366972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
26
|
Protease inhibitors, sexual dysfunction and Viagra. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1999; 13:12. [PMID: 11366202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
27
|
IL-2 taken to HAART. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1999; 13:4-6. [PMID: 11366116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
28
|
Absence makes the HAART grow fonder. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1999; 13:1-4. [PMID: 11366113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
29
|
Drug use and prescribing problems in four state Medicaid programs. HEALTH CARE FINANCING REVIEW 1999; 20:63-78. [PMID: 10558021 PMCID: PMC4194624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
In this article the authors present population-level prevalence rates for 61 specific drug-related problems occurring in three State Medicaid programs (Maryland, Iowa, and Washington) from 1989 through 1996 and a fourth (Georgia) from 1994 through 1996. The findings represent the first application of a consistent drug utilization review (DUR) screener program to Medicaid data across States. The study finds major differences in DUR failure rates among the four States with the lowest rates in Georgia and the highest in Washington. Only Iowa showed any population-level reduction in DUR failure rates during the study period, however, rates for community-dwelling elderly fell in most States.
Collapse
|
30
|
Salvage therapy: still more intuition than data. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1999; 13:6-12. [PMID: 11366112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
31
|
Retrovirus conference report: three new agents to the rescue. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1999; 13:1-4. [PMID: 11366110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
32
|
Abacavir's trials and tribulations. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1998; 12:1-3. [PMID: 11365905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
33
|
Antiviral therapy: how simple can you get? GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1998; 12:3-7. [PMID: 11365906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
34
|
Resistance assay update. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1998; 12:5-7. [PMID: 11365903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
35
|
Access to efavirenz and amprenavir. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1998; 12:12. [PMID: 11365902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
36
|
Crixivan warning: keep to three times a day. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1998; 12:2. [PMID: 11365805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
37
|
Another expensive drug for your cocktail. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1998; 12:3-6. [PMID: 11365806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
38
|
The search for more intelligent therapy. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1998; 12:1-6. [PMID: 11365618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
39
|
Phenotypic assays become widely available. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1998; 12:3-5. [PMID: 11365722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
40
|
A further point about statins.... GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1998; 12:8. [PMID: 11365725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
41
|
T-20 and adefovir for salvage therapy -- expect no miracles. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1998; 12:6-7. [PMID: 11365400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
42
|
Abacavir at last. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1998; 12:9. [PMID: 11365394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
43
|
Moods brighten as statistics lighten. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1998; 12:1-5. [PMID: 11365390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
44
|
Wide-ranging progress on KS therapies. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1998; 12:8-16. [PMID: 11365219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
45
|
Three drugs now in expanded access. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1997; 11:12. [PMID: 11364820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
46
|
DMP 266 now available. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1997; 11:5-6. [PMID: 11364751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
47
|
HIV's impact on women's physique. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1997; 11:7-8. [PMID: 11364658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
48
|
ACTG 300 leaves many questions unanswered. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1997; 11:35-6. [PMID: 11364654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
49
|
Now there are eleven, but so what? GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1997; 11:1-3. [PMID: 11364371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
50
|
No attrition in research on wasting therapies. GMHC TREATMENT ISSUES : THE GAY MEN'S HEALTH CRISIS NEWSLETTER OF EXPERIMENTAL AIDS THERAPIES 1997; 11:9, 12-6. [PMID: 11364378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|